This idea is 8-for-8 on double-digit moves

Swinging for number 9 today 🏏

October 02, 2025

Every time I’ve put this one on the radar in 2025, it has posted a double-digit move that same day. Eight alerts, eight intraday wins. With the stock pushing back toward resistance, I’ll be watching today to see if the streak holds.

TODAY’S TOP ALERT! 

MAIA Biotechnology (NYSE: MAIA)

👉  MAIA is TODAY’S #1 ALERT 👈

Hey there, Folks,

Last month, I wrote to you about one of my favorite stocks. It made double-digit intraday gains all seven times I had alerted it in 2025.

Yeah, I thought that was pretty wild too, so I had to go back and check it a couple of times.

You can say the odds have definitely been favoring my timing on this one!

It was sitting just above a support level, and I was watching it for a bounce.

Sure enough, that day saw a 14% intraday gain, bringing us to 8 for 8 on this stock this year.

It’s no surprise that Zacks Equity Research declared it one of the “Best Momentum Stocks to Buy” earlier this year.

Go to your favorite platform and pull up MAIA Biotechnology, Inc. (MAIA).

You’ll see that it had a huge ramp-up after the trade-war reversal in April. 

From its low on April 10 through early May, it soared an eye-watering 95%.

It gradually pulled back from that high, but since August, it has built a floor around $1.45–$1.50. Every dip into that range has prompted buying.

Yesterday, the stock bounced 7.8% to hit $1.66 — a clean bounce off that base.

It’s now pushing for the $1.75–$1.80 resistance, and I’m watching it today to see if it breaks through.

👉  MAIA is TODAY’S #1 ALERT 👈

For background, MAIA is a clinical-stage biopharmaceutical company exploring genuinely groundbreaking cancer treatments.

Here are some highlights you should consider as you do your own homework on the company right now…

1. A Potential Game-Changer in Cancer Treatment

MAIA’s flagship product, THIO (christened "Ateganosine" in March), is a potential game changer in oncology. 

Ateganosine is the only clinical-stage anticancer agent that targets telomeres, which are like protective caps at the ends of chromosomes that cancer cells exploit to keep dividing endlessly. 

Ateganosine breaks down these caps, triggering rapid cancer cell death while activating the immune system to keep fighting even after treatment stops.

This dual-action approach could revolutionize how we think about cancer therapies. Most existing treatments target the immune system or the cancer cells — not both.

MAIA announced in February its plans “to initiate a Phase 3 pivotal trial in 2025, named THIO-104, to evaluate the efficacy of THIO administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC).”

MAIA’s pipeline

On July 17, MAIA revealed the publication of preclinical data in a leading peer-reviewed journal, Nucleic Acids Research, demonstrating Ateganosine had “a significantly lower 50% inhibitory concentration with superior anticancer efficacy compared with the corresponding monotherapies.”

And on August 27, the company announced it had published developments in its Phase 2 THIO-101 clinical trial in a special issue of the journal Cells called “Cellular Mechanisms of Anti-Cancer Therapies.”

2. FDA Orphan Drug and Fast Track Designations

In the biotech world, exclusivity is crucial. MAIA’s Ateganosine has Orphan Drug Designations from the FDA for small cell lung cancer, hepatocellular carcinoma, and glioblastoma. 

This would mean 7 years of market exclusivity post-approval plus tax credits for clinical trial costs.

SCLC alone kills nearly 125,000 people in the U.S. yearly. If MAIA’s drug proves effective, it could dominate a potentially lucrative market.

And on July 28, MAIA revealed:

CEO Vlad Vitoc noted that “If we are successful in the Fast Track regulatory pathway, ateganosine could qualify for accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.” [emphasis added]

3. Strong Early Data Is Turning Heads

Updated data from its THIO-101 Phase 2 trial — released on September 11 — are incredibly promising. 

In a heavily pre-treated population, ateganosine paired with Regeneron’s Libtayo achieved progression free survival (PFS) of 5.6 months — more than double the 2.5 months for the comparable standard-of-care.

MAIA’s CEO said the data demonstrate “the durability of ateganosine treatment through extended treatment cycles, which is in line with consistent tolerability and low toxicity.”

Results like these can attract big pharma partnerships and investor interest. Ateganosine is showing real potential to disrupt the market.

And just last week, the National Institutes of Health awarded MAIA a $2.3 million grant for the expansion of THIO-101.

They don’t hand those out to just anyone, folks.

MAIA’s senior medical director, Victor Zaporojan, called the grant “a tremendous achievement and a testament to the dedication, collaboration, and hard work of everyone involved in the clinical development of ateganosine.”

4. Partnership with Roche 🤝

On June 18, MAIA revealed a clinical master supply agreement with Roche (yes, $272 billion market cap Roche) “for future studies investigating the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers.”

The two drugs were found to be “highly synergistic” in preclinical studies.

Between this and the Regeneron ($62 billion market cap) partnerships, MAIA’s Ateganosine has attracted attention from some serious pharma heavyweights. 🥊

5. Strong Insider Confidence 💼

Company insiders aren’t just talking, they’re scooping up MAIA shares hand over fist lately:

That’s more than 600,000 shares bought since November alone.

In addition, a company director bought shares in a private placement announced on Monday.

Why It Stands Out:

MAIA isn’t your typical biotech. With a truly novel approach to cancer, strong early data, and heavyweight partnerships, the company could be on the verge of something game-changing. 

In August, Diamond Equity Research released an update note on MAIA highlighting “[r]ecent updates [that] further de-risk the THIO program in third-line [non-small cell lung cancer].”

Incorporating the company’s recent financials, Diamond revised its valuation of MAIA to $10.27 per share — 518% higher than yesterday’s closing price.

Investors looking for exposure to next-gen cancer therapies should do their homework on MAIA immediately, beginning with the company website, as well as the June investor presentation and this March shareholder letter.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: I’ve managed to alert MAIA on eight occasions in 2025 when it went on to make double-digit gains the same day. 

It took off from a very reliable support level yesterday, and I think today could be another big one for the stock.

Stay locked into MAIA for all the action!

To Your Success,

P.S. Don’t forget to join me TODAY in Market Masters for a special teaching session on Crypto - LIVE (and FREE!) at 12:30pm EST. Bring your questions!

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we currently have received twenty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on October 2, 2025. Before this, we received twenty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on September 11, 2025. Before this, we received thirty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on August 27, 2025. Prior to this, we received twenty thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on July 28, 2025. Additionally, we were paid twenty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on July 1, 2025. Before this, we received thirty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on June 18, 2025.  Before this, we received twenty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a two day marketing program starting on May 1, 2025. Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on April 23, 2025. Prior to that, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on March 20, 2025.  Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on February 27, 2025. Prior to that, we received thirty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on January 7, 2025, and we also received fifteen thousand dollars (cash) from Legends Media for advertising MAIA Biotechnology, Inc for a one day marketing program on December 16, 2024, and we received twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on November 7, 2024, and also twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on July 9, 2024 and also fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 13, 2024. Previously, we received twelve thousand five hundred dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 7, 2024. Also, we were paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc for a one day marketing program on March 6, 2024. We were also previously paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15  through November 18, 2023, and also fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. These amounts were paid by someone else not connected to MAIA Biotechnology, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into MAIA Biotechnology, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.